2015 UW Honorary Citiation Report – Rogge

citawards-2015-rogge

Citation recipient Mark Rogge (left) with Dean Steve Swanson (right)

Mark C. Rogge is Senior Director for Early Development Sciences at Biogen Idec Corporation in Cambridge, Mass. He received B.S. and M.S. degrees in pharmacy from the University of Wisconsin-Madison in 1982 and 1984 respectively. He also received a M.S. degree in pharmaceutics and Ph.D. degree in pharmacy from the University of Michigan. Prior to joining Biogen Idec in 2007, he worked for ZymoGenetics and Immunex in Seattle, Wash.

His drug development accomplishments include being a member of teams that developed Levaquin™, Avonex™, Enbrel™, Tecfidera™, and provided oversight on the development of Recothrom™, Plegridy™, Eloctate™, Alprolix™ and Zimbryta. Dr. Rogge is a Fellow in the American College of Clinical Pharmacology (ACCP), has chaired the Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section of the American Association of Pharmaceutical Scientists (AAPS), and is currently the chair of the Clinical Pharmacology Leadership Group for the International Consortium on Innovation and Quality in Pharmaceutical Development. He has served on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences since 2001. He has 48 peer-reviewed publications, nine invited international plenary presentations, 60 podium/poster presentations, three patents, and was co-editor for the book Preclinical Drug Development. As a volunteer he has served on the University of Washington School of Bioengineering Advisory Board, is a founding member of BioSafe (BIO Expert Preclinical Safety& PK/PD Scientific Advisory Committee), serves on a USP Expert Panel on Complex Molecules, and was a founding Leadership Planning Committee member for the University of Wisconsin-Madison Land O’Lakes Conference on Drug Metabolism/ Applied Pharmacokinetics.

Dr. Rogge’s work in biotechnology was fundamental in defining the preclinical and clinical pharmacology properties of therapeutic glycoproteins. This work, in part, defined the regulatory pathway for development of complex molecules and provided a framework for the approval process of biosimilar products. These broader activities, and his specific efforts with the UK National Centre for the Replacement, Refinement & Reduction of Animals in Research, provided significant support for a reduction in animal testing of biotechnology drugs.